Microneedling (Collagen Induction Therapy / Percutaneous Collagen Induction)

Microneedling is a private aesthetic-clinic procedure where a handheld device with very fine needles creates tiny punctures in the skin — too small to see individually, but enough to trigger the skin's natural repair process. Over weeks, the skin lays down new collagen, which gradually softens fine lines, evens out texture, and improves the look of acne scars. It is one of the gentler aesthetic procedures, with 1-2 days of redness rather than the 5-10 days of laser. Camden Medicals does NOT provide microneedling. Three different things share the name. (1) At-home dermarollers (0.25-0.5 mm) sold over the counter — they mainly help skincare serums absorb better; they don't do real collagen-building. (2) Clinician-grade pen devices (Dermapen, SkinPen, the original Genuine Dermaroller) at deeper settings — the proper procedure. (3) RF microneedling (Morpheus8, Genius RF) which adds gentle heat to the needles — more aggressive, see Camden radiofrequency-skin. Pregnancy and breastfeeding: not recommended for elective aesthetic microneedling. Talk to your midwife or GP.

Camden Medicals editorial · Last reviewed 6 May 2026 · Next review May 2027

  • Cross-checked against
  • NHS
  • NICE
  • BNF
  • EFSA
  • FSA
Verifera Evidence ReviewCamden’s own editorial review · evidence-graded, verification in progress — graded, not guessed.

Camden's own editorial team graded each health claim below on the strength of the published evidence — trials weighed with Cochrane RoB 2, systematic reviews with AMSTAR 2, under the CEGA method. See the grade beside every condition.

Class
Other
Typical daily dose
Depth 0.5-2.5 mm depending on indication + body area; 3-6 sessions at 4-6 week intervals typical.
Top use evidence
Moderate
On this page
  1. What it is
  2. At a glance
  3. What people use it for
  4. How it works
  5. Common myths
  6. What people say online
  7. Common online questions
  8. The official position
  9. UK regulatory landscape
  10. Camden's evidence review
  11. Effect matrix — per-condition evidence
  12. Clinical literature review
  13. Safety, interactions & who should avoid it
  14. How to take it
  15. How to spot quality
  16. Commonly combined with
  17. Related ingredients
  18. Verifera® editorial perspective
  19. Sources
  20. How this entry was researched

What it is

The skin has a built-in repair response — when it gets a small injury, it triggers new collagen production and reorganises itself to be stronger. Microneedling uses this on purpose: very fine sterile needles create tiny channels in skin, the skin responds with its repair process, and over weeks the skin lays down more collagen, softens fine lines, and evens out texture.

The three contexts you'll encounter:

At-home dermarollers (0.25-0.5 mm) — sold over-the-counter, handheld rolling devices with rows of tiny needles. They work mainly by creating temporary channels that help skincare serums absorb better. They do NOT reach deep enough to trigger meaningful collagen-building. They're not unsafe if you sterilise the device and use clean serums afterwards, but they're often oversold as "the same as clinic microneedling at home" — they aren't.

Clinician-grade pen devices (0.5-2.5 mm) — the proper procedure, done in CQC-registered clinics. Names you'll see: Dermapen, SkinPen, Genuine Dermaroller (the original UK device), Innopen. A motorised pen drives the needles to a controlled depth chosen for the area being treated. Numbing cream is applied first. Each session is 30-45 minutes; you'll be pink afterwards for 1-2 days, then back to normal. Most people need 3-6 sessions, 4-6 weeks apart, to see the full effect.

RF microneedling — combines the needles with controlled radio-frequency heat at the tip. This is a more intensive variation; downtime is 3-7 days; results sit closer to CO2 laser in strength. See Camden radiofrequency-skin.

The UK pathway if you want to research it:
1. Check the clinic is CQC-registered (for surgical-tier microneedling in England; equivalent registers elsewhere in the UK).
2. Check the practitioner is on JCCP or Save Face.
3. The clinic should use single-use sterile needle cartridges every time. Reused needles are a red flag — infection risk.
4. A proper consultation includes asking about isotretinoin use, pregnancy plans, skin conditions, current skincare routine, and history of cold sores.

At a glance

  • Private aesthetic-clinic procedure. NOT NHS-funded for cosmetic concerns. Camden does NOT provide.
  • 1-2 days of redness, much shorter recovery than laser. Multiple sessions (3-6) over 3-6 months for results.
  • Three different things called "microneedling": at-home dermarollers (mainly help skincare absorb); clinician pens (the real procedure); RF microneedling (adds heat, more aggressive).
  • At-home dermarollers are NOT a cheap version of the clinical procedure. They work at a different depth and do a different thing.
  • CHECK before booking: clinic on the CQC register (for surgical-tier), practitioner on JCCP or Save Face. Single-use sterile needle cartridges every time.
  • NOT recommended in pregnancy or breastfeeding. Talk to your midwife or GP.
  • AVOID for ≥6 months after stopping isotretinoin. Pause topical retinol 3-7 days before; resume 24-48 hours after.

What people use it for

  • Adults with mild-to-moderate photoaging seeking minimal-downtime procedure

    Microneedling at 0.5-1.5 mm depth, 3-6 sessions over 3-6 months, produces measurable improvements in texture, fine lines, mild dyspigmentation. Downtime 1-2 days. Smaller per-session effect than CO2 laser; similar cumulative result over multiple sessions with much lower complication rate. [1]

    Some evidenceModerate

  • Adults with atrophic acne scars

    Strong indication. Multiple RCTs support microneedling for atrophic acne scar appearance reduction at 1.5-2.5 mm depth, 4-6 sessions. UK NICE NG198 acne pathway addresses active acne; scar revision is separate aesthetic context. [4]

    Some evidenceModerate

  • Adults considering at-home dermaroller use

    Consumer dermarollers (0.25-0.5 mm) primarily enhance topical-active absorption rather than deliver true collagen induction. Lower-risk than clinician-grade but with limited aesthetic effect. Cleanliness + sterilisation discipline matters; replace cartridges; antiseptic skin prep before each use.

    Some evidenceLimited

  • Adults with hair loss considering microneedling adjunct to topical minoxidil

    Trial evidence supports microneedling as adjunct to topical minoxidil for androgenetic alopecia (Dhurat 2013 trial; subsequent RCTs). UK NICE pathway for hair loss is GP review + (where indicated) topical minoxidil + (specialist context) finasteride. Microneedling adjunct is private aesthetic-clinic context. [2]

    Some evidenceModerate

  • Pregnant or breastfeeding women

    AVOID elective aesthetic microneedling per UK BAD / RCOG aesthetic-procedures-in-pregnancy guidance. Topical anaesthetics raise additional considerations. [13]

    Some evidenceStrong

  • Adults on isotretinoin

    Often taught as a 6-month contraindication, but a 2017 systematic-review consensus (Spring et al., JAMA Dermatol) found insufficient evidence to delay microneedling and other superficial procedures during or after isotretinoin — the traditional rule rested on three small 1980s case series. Mechanical dermabrasion and fully ablative laser remain the procedures the consensus advises against. Discuss timing with your prescriber. [14]

    Some evidenceLimited

How it works

Skin heals itself constantly. When a small injury happens, the body sends repair signals to the area: clean up the damage, recruit cells that build new tissue, lay down fresh collagen and elastin. Over weeks the new tissue reorganises and the skin ends up stronger and more orderly than before. Microneedling triggers this process on purpose in a controlled way — many tiny injuries spread evenly across the treatment area, all healing at the same time.

At needle depths of 0.5 mm and above, the channels reach the dermis (the deeper layer where collagen lives), and the repair response includes new collagen production. Below 0.5 mm — where at-home dermarollers operate — the response is mostly limited to the surface layer; useful for absorbing skincare, but not enough to drive collagen-building.

The recovery is fast because the channels are very small. The surface seals over within hours; the visible pink lasts 1-2 days; the deeper remodelling continues quietly for weeks. The aesthetic result is gradual — visible at 4-6 weeks, fully developed at 3-6 months after a full course of sessions.

Two safety considerations matter most. First: sterilisation. The needles create direct openings to the bloodstream, so the cartridges must be brand-new and sterile every session. Second: depth control. Too-deep settings or going over the same skin repeatedly can cause "tram-line" scarring instead of healing. Both of these are why the procedure should be done by a trained, registered practitioner — not at home, and not at a clinic that's unwilling to walk you through their training and protocols.

Common myths

Myth""At-home dermarolling gives the same results as professional microneedling.""

RealityConsumer dermarollers (0.25-0.5 mm) primarily enhance topical-active absorption rather than deliver true collagen induction (which requires ≥0.5 mm depth). Effect intensity substantially lower than clinician-grade pen / RF microneedling. Sterilisation discipline matters at any depth.

Myth""Microneedling is the same as RF microneedling.""

RealityRF microneedling adds thermal damage at depth via radiofrequency energy delivered through the needles. Significantly more aggressive than non-RF microneedling; longer downtime; results comparable to fractional CO2. Camden radiofrequency-skin covers RF context.

Myth""You should layer retinol on right after microneedling for amplified results.""

RealityBackwards. Post-procedure micro-channels enhance penetration of retinol substantially — risk of contact dermatitis + over-irritation. Defer retinol 24-48 hours after procedure; use bland hydrators (HA, peptides, growth-factor serums) immediately post.

Myth""Microneedling works after one session.""

RealityMultiple sessions (typically 3-6 at 4-6 week intervals) deliver cumulative remodelling effect. Single-session results are visible (mild plumping + glow from initial collagen-induction phase) but full aesthetic outcome emerges over 3-6 months.

What people say online

Microneedling is one of the most-searched aesthetic procedures on TikTok, with at-home dermaroller content dominating the consumer-facing discourse. Reddit r/SkincareAddiction and r/30PlusSkinCare host more substantive technical discussion (depth selection, sterilisation, post-procedure routine). The hair-loss adjunct context (microneedling + minoxidil) drives a separate cluster on r/tressless and #hairtok. UK consumers are particularly served by the at-home content (consumer dermarollers are widely available) but the depth + sterilisation requirements are often under-explained. This section surfaces the discourse without naming individuals.

Trending claims

  • TikTok + Reddit (r/SkincareAddiction)high visibility

    Claim: Dermarolling at home gives the same results as professional microneedling

    Reality check: Consumer dermarollers (0.25-0.5 mm depth) primarily enhance topical-active absorption rather than deliver true collagen induction (which requires ≥0.5 mm depth into the dermis). Effect intensity substantially lower than clinician-grade pen (0.5-2.5 mm) or RF microneedling. Sterilisation discipline matters at any depth.

  • TikTok (skincare optimisation content)high visibility

    Claim: Add retinol right after microneedling for amplified results

    Reality check: Backwards advice. Post-procedure micro-channels enhance retinol penetration substantially — risk of contact dermatitis and over-irritation rises. Defer retinol 24-48 hours after procedure; use bland hydrators (HA, peptides, growth-factor serums) immediately post.

  • TikTok (#hairtok, #tressless)high visibility

    Claim: Microneedling regrows hair when minoxidil stops working

    Reality check: Trial evidence supports microneedling + minoxidil combination outperforming minoxidil alone in androgenetic alopecia (Dhurat 2013, PMID 23960389; n=100; mean hair count change 91.4 vs 22.2 at 12 weeks). NHS hair-loss pathway is GP review + topical minoxidil; microneedling adjunct is private aesthetic-clinic context. Not a replacement for the evidenced UK pathway. [8,2]

  • TikTok before/after contenthigh visibility

    Claim: Microneedling shows results after one session

    Reality check: Multiple sessions (typically 3-6 at 4-6 week intervals) deliver cumulative remodelling effect. Single-session results are visible (mild plumping + glow from initial collagen-induction phase) but full aesthetic outcome emerges over 3-6 months (Abdelhay 2024, PMID 39442178; He 2025, PMID 40931569 — both used 4-session protocols). [10,11]

Where the conversation lives

  • TikTok hashtags: #microneedling, #dermaroller, #microneedlingathome, #hairtok, #tressless
  • Reddit subs: r/SkincareAddiction, r/30PlusSkinCare, r/tressless, r/HaircareScience
  • Forums: RealSelf microneedling discussions (US comparator)

Questions people are searching

  • Is at-home microneedling worth it?
  • Microneedling vs RF microneedling — what's the difference?
  • Can microneedling regrow my hair?
  • What depth dermaroller should I use?
  • How often should I microneedle?

Who drives the discourse: The discourse is driven by three influencer classes: aesthetic- medicine practitioner creators (most evidence-anchored on UK CQC / JCCP context); skincare-influencer creators (highest reach, variable evidence-anchoring); and hair-loss community creators (technically engaged on minoxidil adjunct claims). Verifera editorial does not name individuals.

Social-media trends change quickly. This section is editorial commentary on what people are searching for — not a recommendation.

Common online questions

Synthesised from the questions UK shoppers most often ask online about Microneedling (Collagen Induction Therapy / Percutaneous Collagen Induction). Each answer is editorial and links to its evidence in the Sources list below.

How is microneedling different from CO2 laser?

Mechanical needle penetration (microneedling) vs thermal ablation (CO2). Microneedling: shorter downtime (1-2 days vs 5-10 days), lower complication rate, smaller per-session effect, multiple sessions required. CO2: longer downtime, higher complication rate (post-inflammatory hyperpigmentation in darker skin types), fewer sessions for equivalent aesthetic outcome. Different patient-procedure matching contexts.

What's RF microneedling and is it worth the upgrade?

RF microneedling (Morpheus8, Genius RF, INTRAcel, Vivace) adds radiofrequency thermal damage at-depth via the needles. Closer to CO2 laser intensity with ~3-7 day downtime + lower complication rate than CO2. More expensive; better for moderate-to-severe photoaging or deep atrophic scars. Camden radiofrequency-skin covers RF context.

How do I find a UK microneedling practitioner?

Look for: CQC registration (clinic level if surgical-tier); JCCP or Save Face practitioner registration; GMC / GDC / NMC registration if medical / dental / nursing provider. Avoid practitioners without verifiable training + sterile single-use needle cartridges. Camden does NOT provide microneedling. [1]

Should I stop my retinol before microneedling?

Yes — pause topical retinoids (retinol / retinal / tretinoin / adapalene / tazarotene) 3-7 days before procedure. Resume 24-48 hours after re-epithelialisation. Use bland hydrators (HA, peptides) immediately post-procedure.

⚖️ The official position

What may lawfully be claimed about Microneedling (Collagen Induction Therapy / Percutaneous Collagen Induction) in Great Britain. This is a regulatory position, not an evidence grade.

No health claim is authorised for Microneedling (Collagen Induction Therapy / Percutaneous Collagen Induction) in Great Britain.

This page describes the evidence and online discussion without making a claim.

UK regulatory landscape

UK regulatory tier: Medical device

Microneedling devices are regulated as Class IIa (clinician- grade pen) to Class IIb (RF microneedling) medical devices under the UK MDR 2002 + assimilated EU MDR 2017/745. Consumer dermarollers (0.25-0.5 mm depth) sold for at-home use are typically Class I (lower-risk) where marketed for cosmetic use. The aesthetic-medicine PROVIDER is subject to CQC registration when delivering surgical-tier microneedling (deeper depths, RF microneedling) in England, with equivalent frameworks elsewhere in the UK. The INDIVIDUAL practitioner is subject to JCCP and Save Face professional registration. NHS does NOT provide microneedling for aesthetic indications.

What crosses the tier

ConditionCrosses to
Marketing language implies treatment of a medical condition (active acne, eczema, alopecia areata, vitiligo)Crosses to medicinal-treatment / MHRA Borderline classification. Aesthetic-clinic marketing under those framings is non-compliant.
Provider lacks CQC registration but delivers surgical-tier microneedling in EnglandCQC enforcement; provider may be required to cease operating until registered.
Consumer dermaroller marketed for true collagen-induction outcomes (vs topical-absorption enhancement)Outside the trial-evidence boundaries for 0.25-0.5 mm depth devices. ASA / CAP Code §12 substantiation concerns.

Permitted claims

Aesthetic-procedure marketing claims must be substantiated + truthful + decent + honest under the UK ASA / CAP Code (§12 on medicines, medical devices, health-related products and beauty products). Permitted: descriptive procedure claims, demonstrable cosmetic benefits supported by trial evidence, transparent disclosure of CQC / JCCP / Save Face registration. NOT permitted: medical-condition treatment claims, "permanent" framing, before / after images that exceed trial-evidence average effect size.

EFSA claim status

Aesthetic procedure regulated under UK Medical Devices Regulations + CQC registration framework, NOT under EU Nutrition and Health Claims Regulation 1924/2006.

Cross-jurisdiction note

US aesthetic-microneedling regulation operates under FDA Class II device pathway. US-clinic-centred TikTok content (including RealSelf reviews) does NOT translate directly to the UK delivery model — UK consumers should not assume US protocols apply in their local clinic context.

UK regulatory rules evolve. This summary is editorial — businesses should consult regulatory counsel; consumers should consult their pharmacist or GP.

🔬 Camden’s evidence review

The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.

  1. Photoaging — fine lines, texture

    Evidencemoderate

    Multiple RCTs support microneedling for photoaging-marker improvements over 3-6 sessions. [1]

  2. Atrophic acne scars

    Evidencemoderate

    Strong indication; RCT evidence for atrophic acne scar appearance reduction. [4,15,16,17]

  3. Androgenetic alopecia (with topical minoxidil)

    Evidencemoderate

    Dhurat 2013 trial + subsequent RCTs support microneedling adjunct to topical minoxidil for androgenetic alopecia. UK NHS pathway is GP review + topical minoxidil first-line. [2,18,19,20]

  4. Stretch marks (striae)

    Evidencelimited

    Some trial evidence for early-phase striae rubrae. UK NHS does not specifically endorse microneedling for stretch marks. [3,21,22,23]

Effect matrix — per-condition evidence

Per-outcome summary of the published trial corpus: dose ranges studied, duration, evidence grade, and direction of effect. Each row is a citable claim.

OutcomePopulationDoseDurationEvidenceDirectionSources
Atrophic acne scarsadults—12–24 wkEvidencelimitedimprovementPMID 39442178 PMID 40931569 PMID 33538106 PMID 36749436 PMID 37067138
Procedure dose: 3-6 sessions at 4-6 week intervals; 1.5-2.5 mm depth typical for atrophic-scar protocols. Abdelhay 2024 (n=21 split-face) confirmed microneedling-alone efficacy on Goodman & Baron + Lipper & Perez scores; He 2025 (n=20 split-face) RF microneedling + ablative fractional laser superior to fractional laser alone (ECCA reduction 53.5% vs 41.7%). Convention B1 — sessions field pending A1 enum extension.
Striae distensae (stretch marks)adults—12–24 wkEvidencelimitedimprovementPMID 20885236 PMID 40131559 PMID 38509316 PMID 40106114
Procedure dose: 3-4 PCI sessions at 1.5-2.0 mm depth. Aust 2010 documented measurable width, depth, and pigmentation improvement on early-phase (red) striae rubrae at 6-month follow-up. Mature white striae less responsive. Modest effect size; early intervention favoured.
Androgenetic alopecia (hair regrowth, minoxidil adjunct)adults—12–24 wkEvidencemoderateimprovementPMID 23960389 PMID 40056230 PMID 37665358 PMID 32478968
Procedure dose: weekly microneedling for 12 weeks at 1.5 mm depth + twice-daily 5% topical minoxidil. Dhurat 2013 (n=100 randomised, evaluator-blinded) — mean hair count change 91.4 (microneedling + minoxidil) vs 22.2 (minoxidil-only) at week 12; 82% vs 4.5% reported >50% improvement. UK NHS pathway is GP review + topical minoxidil first; microneedling adjunct is private aesthetic-clinic context. Landmark trial; confirmatory replication still limited.
Melasmaadults—12–24 wkEvidencelimitedmixedPMID 40220134
Procedure dose: 3-6 sessions, depth + interval practitioner-determined; PIH risk concern in Fitzpatrick IV-VI. Hema 2025 review notes microneedling for melasma — mixed direction-of-effect across the small trial body; PIH adverse-event risk meaningful for the same population melasma affects most. Outcome highly operator-dependent. Treat as exploratory rather than first-line.
Adverse effect — Post-inflammatory hyperpigmentation (adverse event)adults—1–12 wkEvidencelimiteddecrementPMID 40220134 PMID 34448760
Hema 2025 review identifies temporary erythema and PIH as most-reported adverse events; severe or permanent effects rare. Risk concentrated in Fitzpatrick IV-VI skin tones. Practitioner-skill and sterilisation discipline are load-bearing. Camden does NOT provide microneedling; UK CQC/JCCP/Save Face framework applies.

Evidence grades run Strong › Moderate › Limited › Very limited › Insufficient. Direction is the consensus of the published trials: improvement, no change, mixed, or decrement. A row marked Adverse effect is graded on the strength of the evidence of harm, not of benefit.

Clinical literature review

The microneedling literature spans three principal application areas — photoaging, atrophic acne scarring, and androgenetic alopecia (adjunct to topical minoxidil). Mechanism evidence is well-established: micro-channel injury triggers PDGF / TGF-β / FGF growth-factor release, fibroblast collagen synthesis, and over weeks-to-months a type-I collagen + elastin remodelling response. The strongest RCT evidence is in androgenetic alopecia adjunct context (Dhurat 2013, PMID 23960389, n=100 RCT showing microneedling + 5% minoxidil superior to minoxidil alone). The atrophic acne scar evidence base includes multiple split-face RCTs (Abdelhay 2024, PMID 39442178 — microneedling ± topical insulin; He 2025, PMID 40931569 — alternating fractional laser + RF microneedling vs fractional laser alone). Recent reviews (Hema 2025, PMID 40220134) summarise the broader topical drug-delivery enhancement potential. The structural weaknesses are small sample sizes (n=5-50 typical), single-centre design, variable outcome assessment, and limited UK-specific data.

Key trials

  • Dhurat R et al. · 2013 · Int J Trichology · PMID 23960389

    Design: Randomised evaluator-blinded study (pilot) · n = 100 · Duration: 12 weeks

    Finding: Mild-to-moderate androgenetic alopecia (Hamilton-Norwood III vertex or IV) — weekly microneedling + twice-daily 5% minoxidil vs 5% minoxidil alone. Mean change in hair count at week 12 was 91.4 (microneedling group) vs 22.2 (minoxidil-only group). 82% of microneedling-group patients reported >50% improvement vs 4.5% in minoxidil group. Microneedling effective for hair loss refractory to minoxidil.

    Relevance: Landmark hair-loss adjunct trial. UK NHS hair-loss pathway starts with GP review + topical minoxidil; microneedling adjunct is private aesthetic-clinic context. This trial underpins the microneedling-as-minoxidil-adjunct positioning.

  • Aust MC et al. · 2010 · Plast Reconstr Surg · PMID 20885236

    Design: Cohort study (consecutive case series) · Duration: Follow-up 6 months

    Finding: Percutaneous collagen induction (PCI) therapy for striae distensae — early-phase striae rubrae showed measurable improvement in width, depth, and pigmentation over 6-month follow-up after 3-4 PCI sessions at 1.5-2.0 mm depth.

    Relevance: Established the PCI / microneedling indication for striae distensae. Subsequent trials confirm modest effect on early-phase (red) striae; mature white striae less responsive.

  • Abdelhay RM et al. · 2024 · Dermatol Surg · PMID 39442178

    Design: Randomised split-face RCT · n = 21 · Duration: 12 weeks (4 sessions × 3-week intervals) + 1 month follow-up

    Finding: Atrophic post-acne scars treated split-face with microneedling (Dermapen) followed by topical insulin vs microneedling followed by saline. Both modalities produced statistically significant improvement in Goodman & Baron and Lipper & Perez scar scores; no significant between-side difference. Adverse events comparable.

    Relevance: Recent UK-relevant evidence on microneedling for atrophic acne scars. Confirms microneedling-alone efficacy; combination with topical insulin is exploratory, not yet standard.

  • He H et al. · 2025 · J Dtsch Dermatol Ges · PMID 40931569

    Design: Prospective randomised single-blind split-face RCT · n = 20 · Duration: 24 weeks

    Finding: Moderate-to-severe acne scars in Fitzpatrick III-IV — four treatments at 4-week intervals, alternating fractional microneedling RF (sessions 1, 3) + ablative fractional laser (sessions 2, 4) vs ablative fractional laser alone. Alternating therapy achieved ECCA score reduction 53.5% vs 41.7% (p<0.05) and superior sebum reduction. Procedural pain higher in alternating group (VAS 5.8 vs 4.6); adverse events comparable.

    Relevance: Most recent comparative evidence on RF microneedling within a clinical sequencing protocol — supports the cluster framing that RF microneedling complements ablative fractional laser rather than substituting for it.

Systematic reviews

  • pmid:40220134

    Hema et al. 2025 review of microneedling technology covers acne, scars, alopecia, melasma, skin rejuvenation, and photo-damage applications. Temporary erythema and post- inflammatory hyperpigmentation are the most-reported adverse events; severe or permanent effects rare. Calls for larger randomised trials to establish safety + efficacy across diverse populations.

  • pmid:34448760

    Chu et al. 2021 (Dermatol Surg) systematic review of 85 studies on the microneedling safety profile identifies post-inflammatory hyperpigmentation (PIH) as both a common transient post-procedure adverse event and, less commonly, a persistent serious effect alongside tram-track scarring and granulomatous reactions. Risk is concentrated in darker (Fitzpatrick IV-VI) skin types, active infection, and metal-allergy contexts. Confirms PIH as a microneedling-specific documented adverse event.

Evidence quality summary

Photoaging — MODERATE certainty (multiple small RCTs, consistent direction of effect at 0.5-1.5 mm depth + 3-6 sessions). Atrophic acne scars — MODERATE certainty (multiple split-face RCTs, including 2024 + 2025 contemporary trials; effect at 1.5-2.5 mm depth, 4-6 sessions). Androgenetic alopecia adjunct — MODERATE certainty (Dhurat 2013 landmark RCT + subsequent confirmatory studies). Striae distensae — LIMITED certainty (effect modest; early striae rubrae most responsive). Topical drug-delivery enhancement — MECHANISM-STRONG / CLINICAL-LIMITED. Adverse- event profile is well-tolerated when sterilisation discipline and practitioner training are adequate.

Known gaps

  • Limited head-to-head RCT data comparing non-RF microneedling vs RF microneedling vs fractional laser.
  • At-home dermaroller (0.25-0.5 mm) collagen-induction effect under-studied — most consumer-grade evidence is anecdotal.
  • Long-term (>12 month) outcome data limited.
  • Tram-line scarring incidence under-reported in published evidence — practitioner-skill variable.
  • UK-specific clinical-outcome data sparse; most trials are international.

This summarises the published evidence as of the last review date — it is not advice for your specific situation. Talk to your pharmacist or GP.

Safety

Microneedling among the safer aesthetic interventions when properly performed. Sterilisation discipline + practitioner training matter. Camden does NOT provide.

Talk to your pharmacist or GP first if you:

  • You are pregnant or breastfeeding — defer.
  • You are on isotretinoin within 6 months — contraindicated.
  • You take immunosuppressants — wound-healing concern.
  • You have active acne, rosacea, or eczema flare in the area — defer.
  • You have a history of keloid scarring — high-risk.
  • You take warfarin / DOAC — modest bleeding-risk consideration.
  • You take photosensitising medication — increased post-procedure photosensitivity.

Common side effects: Erythema, mild swelling, pinpoint bleeding 1-2 days. Rare: infection, post-inflammatory hyperpigmentation, tram-line scarring with incorrect depth.

Pregnancy and breastfeeding

Elective aesthetic microneedling is not recommended in pregnancy per UK BAD / RCOG aesthetic-procedures-in-pregnancy guidance. Topical anaesthetics + post-procedure analgesia raise additional considerations. Talk to your midwife or GP if you are uncertain.

Elective aesthetic microneedling is not recommended during breastfeeding for the same defer-to-after-feeding rationale. Talk to your midwife or GP.

Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.

More clinical detail (for clinicians and informed readers)

Contraindications

  • Pregnancy and breastfeeding (UK BAD / RCOG).
  • Concurrent oral isotretinoin or within 6 months of stopping.
  • Concurrent immunosuppressants.
  • Active acne, rosacea, eczema flare in the treatment area.
  • Active herpes simplex outbreak (relative).
  • History of keloid or hypertrophic scarring.
  • Bleeding disorders / concurrent anticoagulant without practitioner adjustment.
  • Hypersensitivity to topical anaesthetics.

Drug interactions

  • Oral isotretinoin (Roaccutane, Reticutan, generics) · high

    Effect: Impaired wound healing + hypertrophic-scarring risk during the isotretinoin course and for ≥6 months after stopping. CONTRAINDICATION-LEVEL for clinician-grade microneedling (and especially RF microneedling).

    Mechanism: Systemic 13-cis-retinoic acid suppresses sebocyte function and impairs wound-healing kinetics — microneedling-induced micro-channels heal abnormally.

    Action: Tell your dermatologist or aesthetic-medicine practitioner about any oral isotretinoin use in the last 6-12 months; the procedure should be deferred until wash-out is documented.

    Source: Camden isotretinoin entry + clinic protocols

  • Topical retinoids (tretinoin, adapalene, tazarotene, retinol, retinal) · medium

    Effect: Pre-procedure pause of 3-7 days normalises stratum corneum; post-procedure pause of 24-48 hours prevents penetration- enhanced contact dermatitis through the micro-channels.

    Mechanism: Active retinoid signalling combined with enhanced penetration through temporary micro-channels can drive contact dermatitis and irritation.

    Action: Talk to your dermatologist, GP, or aesthetic-medicine practitioner about retinoid pause timing relative to your procedure date.

    Source: Camden retinol + retinal entries

  • Anticoagulants (warfarin, DOACs) · low

    Effect: Modest bleeding-risk consideration; pinpoint bleeding during microneedling is normal and self-limiting, but anticoagulant use raises the volume and may delay haemostasis.

    Mechanism: Reduced coagulation cascade efficiency at the micro-channel bleeding sites.

    Action: Tell your anticoagulation clinic and the aesthetic-medicine practitioner. Do not adjust anticoagulant dose without prescriber instruction.

    Source: BNF anticoagulation

  • Photosensitising medications (doxycycline, amiodarone, hydrochlorothiazide) · medium

    Effect: Increased post-procedure photosensitivity during the 1-2 week recovery + SPF window; PIH risk amplified.

    Mechanism: Drug-induced photosensitivity combines with the post- procedure barrier compromise to magnify UV-induced pigmentation.

    Action: Tell your prescriber and the aesthetic-medicine practitioner about any long-term photosensitising medication; SPF 50+ discipline becomes even more critical.

    Source: BNF photosensitivity drug list

  • Systemic immunosuppressants (post-transplant regimens, biologics) · high

    Effect: Impaired wound healing + infection risk; procedure typically deferred during active immunosuppression.

    Mechanism: Suppressed neutrophil + fibroblast function delays the wound-healing cascade that drives both recovery and the cosmetic outcome.

    Action: Talk to the prescribing team (transplant / rheumatology / dermatology) before any microneedling.

    Source: BNF immunosuppression

Tell your prescriber if you take any of these combinations. This is not personalised advice.

This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.

Common side effects

  • Erythema, mild swelling, pinpoint bleeding 1-2 days.
  • Mild discomfort during procedure.
  • Skin dryness 3-5 days.

Rare side effects

  • Bacterial / viral infection (sterilisation discipline matters).
  • Post-inflammatory hyperpigmentation (higher risk in Fitzpatrick IV-VI).
  • Tram-line scarring (incorrect depth + repeated coverage).
  • HSV reactivation.
  • Hypertrophic scarring (rare; isotretinoin / immunosuppressant context).

How to take it

Typical supplemental range
Depth 0.5-2.5 mm depending on indication + body area; 3-6 sessions at 4-6 week intervals typical.
Timing
Procedure-based.

How to spot quality

Look for

  • CQC registration (clinic level if surgical-tier).
  • JCCP or Save Face practitioner registration.
  • Single-use sterile needle cartridges.
  • Antiseptic skin preparation pre-procedure.
  • Pre-procedure consultation including topical-retinoid pause + isotretinoin history.
  • GMC / GDC / NMC if medical / dental / nursing provider.
  • Genuine Dermaroller / SkinPen / Dermapen / INTRAcel / Morpheus8 / Genius RF (verified device branding).

Red flags

  • No CQC / JCCP / Save Face registration.
  • Reused needle cartridges (cross-infection risk).
  • No antiseptic skin prep.
  • No isotretinoin / pregnancy history check.
  • Promotional discounts that bypass consultation.
  • At-home dermaroller marketed for true collagen-induction outcomes (consumer-grade is primarily topical-absorption enhancement).

Commonly combined with

Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.

Polypeptides (Cosmetic peptides — signal / carrier / neurotransmitter-inhibiting)

Limited evidence

Post-procedure fibroblast-signal adjunct — peptide serums penetrate substantially better through micro-channels; mechanism-complementary with the wound-healing cascade.

Cosmetic peptides (Matrixyl signal peptides, GHK-Cu carrier peptides) provide direct fibroblast / wound-healing signal. Microneedling triggers the same wound-healing cascade. The temporary micro-channels enhance peptide penetration. Mechanism-additive.

Evidence: Mechanism complementary; peptide-microneedling combination products well-marketed.

Doses studied: Post-procedure: peptide serum applied 24-48h after re-epithelialisation; signal peptide + carrier peptide combinations.

Vitamin C topical (L-ascorbic acid + ester derivatives)

Limited evidence

Post-procedure antioxidant adjunct — defer 24-48h post for re-epithelialisation; LAA at pH 3-3.5 is too irritating immediately post.

Vitamin C antioxidant + procollagen cofactor; compatible after re-epithelialisation. Defer LAA 24-48h post-procedure; pH-stable derivatives (THD ascorbate) gentler choice immediately post.

Evidence: Compatible adjunct after re-epithelialisation.

Doses studied: Post-procedure day 2+: 5-15% THD ascorbate or pH-stable derivative; day 5+: 10-20% LAA AM.

Niacinamide (Topical, Vitamin B3 amide form)

Limited evidence

Post-procedure barrier-rebuild adjunct — niacinamide ceramide / FFA synthesis support compatible immediately post.

Niacinamide barrier-rebuild mechanism compatible with wound-healing cascade. Pregnancy-safe. Use immediately post-procedure.

Evidence: Compatible adjunct immediately post.

Doses studied: Post-procedure: 5% niacinamide AM + PM.

CO2 Laser (Carbon Dioxide Fractional / Ablative Laser Resurfacing)

Limited evidence

Aesthetic-procedure cluster sibling — sometimes sequenced (microneedling for maintenance between CO2 sessions).

Different mechanisms targeting overlapping outcomes; clinical sequencing at practitioner discretion.

Evidence: Combination at clinician discretion.

Doses studied: Practitioner-determined.

Radiofrequency Skin Tightening (RF Skin Therapy / Subdermal RF Heating)

Limited evidence

Cluster sibling — RF microneedling combines both mechanisms. RF-only skin tightening + microneedling are different procedures.

RF microneedling = needles + RF energy at-depth. RF-only = surface electrode delivery. Different intensities.

Evidence: Cluster overlap.

Doses studied: Practitioner-determined sequencing.

Related ingredients

Verifera® editorial perspective

Why it matters. Microneedling is the highest-volume aesthetic-procedure search cluster on TikTok, with #dermaroller and #microneedling aggregating hundreds of millions of views. The dominant narratives split between at-home dermarolling content (low cost, low risk if done correctly, modest results) and clinician-grade or RF-microneedling content (higher cost, more substantive remodelling). The Verifera editorial position is that this entry should disambiguate the three device classes clearly (consumer dermaroller vs clinician pen vs RF microneedling) and refer to the UK CQC / JCCP / Save Face framework for clinical-tier procedures.

Where Camden lands. Camden Medicals does NOT provide microneedling procedures and does NOT retail dermarollers or microneedling devices. Camden's commercial scope is oral food supplements + topical cosmetic ingredients. This entry exists as a UK-regulatory-anchored reference for consumers researching the aesthetic-procedure cluster.

If you want to explore further. For UK consumers researching the procedure: the NHS cosmetic- procedures page is the starting reference; the CQC, JCCP, and Save Face registers list registered clinics and practitioners. For clinically-meaningful hair loss, the appropriate pathway is GP review (NHS hair-loss page covers iron / thyroid / nutritional work-up + UK-licensed options of topical minoxidil and oral finasteride for male pattern). For androgenetic alopecia adjunct trials, talk to a GP or trichology specialist.

Verifera® editorial · Last reviewed 6 May 2026

Editorial is educational, not personalised medical advice. Talk to your pharmacist or GP for advice on your specific situation.

Sources

Numbered references cited above plus general authoritative reading. Citations in the body link to the matching number here.

How to read these sources:

  • Tier 1 (UK authoritative): NHS, NICE, BNF, EFSA, FSA, GB NHC Register, SACN, MHRA.
  • Tier 2 (primary literature): peer-reviewed RCTs cited by PMID.
  • Tier 3 (mechanistic): in-vitro / animal-model literature — interpret with caveat.
  1. NHS — Cosmetic procedures
  2. NHS — Hair loss
  3. NHS — Stretch marks
  4. NICE NG198 — Acne vulgaris management
  5. CQC — Care Quality Commission
  6. JCCP — Joint Council for Cosmetic Practitioners
  7. Save Face — practitioner register
  8. Dhurat R et al. (2013) — Microneedling + minoxidil for androgenetic alopecia RCT (Int J Trichology; PMID 23960389)
  9. Aust MC et al. (2010) — Percutaneous collagen induction for striae distensae (Plast Reconstr Surg; PMID 20885236)
  10. Abdelhay RM et al. (2024) — Microneedling ± topical insulin for atrophic acne scars (Dermatol Surg; PMID 39442178)
  11. He H et al. (2025) — Alternating fractional laser + RF microneedling vs laser alone for acne scars (JDDG; PMID 40931569)
  12. Hema et al. (2025) — Microneedle technology for topical drug delivery review (Arch Dermatol Res; PMID 40220134)
  13. NHS — pregnancy › keeping well › have a healthy diet
  14. PubMed PMID 28658462
  15. PubMed PMID 33538106
  16. PubMed PMID 36749436
  17. PubMed PMID 37067138
  18. PubMed PMID 40056230
  19. PubMed PMID 37665358
  20. PubMed PMID 32478968
  21. PubMed PMID 40131559
  22. PubMed PMID 38509316
  23. PubMed PMID 40106114

How this entry was researched

Authoritative sources consulted:

  • NHS cosmetic-procedures + hair-loss + stretch-marks pages
  • NICE NG198 acne vulgaris guideline
  • UK MDR 2002 + EU MDR 2017/745 (Class IIa-IIb medical-device framework)
  • CQC register of cosmetic clinics
  • JCCP register of cosmetic practitioners
  • Save Face register of accredited practitioners
  • BAD consensus statements on aesthetic procedures
  • PubMed (via E-utilities MCP)

PubMed search terms:

  • microneedling collagen induction therapy acne scars randomized
  • Aust percutaneous collagen induction microneedling
  • Dhurat microneedling minoxidil androgenetic alopecia
  • fractional microneedling radiofrequency acne scar

Literature search date: 2026-05-11

Sources listed are those consulted by the Verifera® editorial team. Readers should verify against current authoritative sources.

Verifera® is published by Camden Medicals — a UK supplement retailer. We have a commercial interest in some of the ingredients described here; we declare it on every page and our editorial process forbids adjusting copy to favour our own products. Read our editorial policy.

This page is information, not medical advice. Talk to your pharmacist or GP before starting any supplement, especially if you take prescribed medicines, are pregnant or breastfeeding, or have an existing condition.

Suspected side effects can be reported to the MHRA via the Yellow Card scheme: yellowcard.mhra.gov.uk